<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-657" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Bisoprolol</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bazroon</surname>
            <given-names>Ali A.</given-names>
          </name>
          <aff>Imam Abdulrahman Bin Faisal University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Alrashidi</surname>
            <given-names>Nada F.</given-names>
          </name>
          <aff>Imam Abdulrahman Bin Faisal University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ali Bazroon declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Nada Alrashidi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-657.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Bisoprolol is a medication used to manage and treat hypertension and congestive heart failure.&#x000a0;The drug belongs to the selective beta-blocker class of drugs and acts explicitly as a cardioselective beta1-blocker (B1-blocker). Bisoprolol mainly focuses on beta1 receptors in the heart to address several heart conditions, such as congestive heart failure.&#x000a0;The drug does not affect the undesirable B2 receptors, which could affect different bodily systems. Selective B1-blockers, including bisoprolol, have adverse inotropic and chronotropic effects, decreasing heart contractions and heart rate. Consequently, bisoprolol reduces the oxygen consumption of myocardial cells, relieving the heart's workload. B1 receptors are also present in the juxtaglomerular cells of the kidneys. By blocking these receptors, bisoprolol reduces the release of renin, thereby blocking the activation of the renin-angiotensin system. This dual action on the heart and kidneys makes bisoprolol effective in managing hypertension and related conditions.</p>
        <p>This activity discusses the indications, mechanism of action, and contraindications for bisoprolol in managing hypertension and other relevant disorders.&#x000a0;This resource also covers the adverse event profile and other key factors, including the off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, and relevant interactions of bisoprolol, pertinent to interprofessional healthcare teams&#x000a0;when treating patients with hypertension and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify appropriate indications for bisoprolol therapy, including hypertension, heart failure, and certain arrhythmias.</p></list-item><list-item><p>Screen patients for contraindications and risk factors before initiating bisoprolol treatment, such as bradycardia, heart block, asthma, or severe peripheral vascular disease.</p></list-item><list-item><p>Assess patients' response to bisoprolol therapy, monitoring blood pressure, heart rate, and signs of adverse effects.</p></list-item><list-item><p>Apply evidence-based guidelines and clinical recommendations to optimize bisoprolol therapy for individual patients.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=657&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=657">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-657.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Bisoprolol is a cardioselective beta1-blocker (B1-blocker). Selective B1-blockers are used to treat multiple heart diseases, such as congestive heart failure, without having the unwanted effect of the B2 receptor blocking, which can affect various systems in the body.<xref ref-type="bibr" rid="article-657.r1">[1]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Bisoprolol&#x000a0;is FDA-approved for&#x000a0;the management of hypertension.&#x000a0;Clinicians must recognize that according to ACC/AHA guidelines, bisoprolol or other beta blockers are not the first-line treatment for hypertension unless the patient has ischemic heart disease or HFrEF.<xref ref-type="bibr" rid="article-657.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>Bisoprolol is used in the treatment plan for compensated heart failure. According to 2022 AHA/ACC/HFSA guidelines, specific beta-blockers (bisoprolol, metoprolol succinate, and carvedilol) are included in guideline-directed medical therapy(GDMT) for heart failure with reduced ejection fraction(HFrEF). Bisoprolol&#x000a0;is recommended to reduce&#x000a0;mortality and hospitalizations in patients with HFrEF.<xref ref-type="bibr" rid="article-657.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>Selective B1- blockers are used as the first-line treatment for chronic stable angina.<xref ref-type="bibr" rid="article-657.r4">[4]</xref>&#x000a0;According to the&#x000a0;2020 International Society of Hypertension practice guidelines, cardioselective beta-blockers such as bisoprolol should be used (with or without calcium channel blockers) in patients with coronary artery disease.<xref ref-type="bibr" rid="article-657.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>The use of bisoprolol correlates with decreased morbidity and mortality post-MI.<xref ref-type="bibr" rid="article-657.r6">[6]</xref> Bisoprolol reduces the risk of stroke and coronary artery disease in patients with heart disease.<xref ref-type="bibr" rid="article-657.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>Non-FDA-approved uses of bisoprolol include the treatment of migraine,&#x000a0;arrhythmia, and tremors; as an anxiolytic for some athletes and musicians.<xref ref-type="bibr" rid="article-657.r8">[8]</xref><xref ref-type="bibr" rid="article-657.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>A fixed-dose combination of bisoprolol and hydrochlorothiazide is approved by FDA for&#x000a0;managing hypertension.<xref ref-type="bibr" rid="article-657.r10">[10]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-657.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Selective B1 blocker drugs have negative inotropic and chronotropic effects; they decrease heart contractions and heart rate. As a net result, bisoprolol reduces the oxygen consumption of myocardial cells. B1 receptors are also present&#x000a0;in the juxtaglomerular cells. By blocking these receptors, bisoprolol leads to a decrease in the release of renin; as a result,&#x000a0;this decrease in renin blocks the activation of the renin-angiotensin system.<xref ref-type="bibr" rid="article-657.r11">[11]</xref></p>
        <p>B1 adrenergic receptors are present&#x000a0;in cardiac myocyte cells and juxtaglomerular cells. They couple with the G-stimulatory protein receptor (Gs receptor) and become stimulated by either norepinephrine or circulating catecholamine. Activation of B1 receptors in cardiac myocytes leads to positive chronotropic and inotropic effects; therefore, the net result will be increased heart rate, contraction, and the strength of myocyte contraction by activating Gs receptors (by the exchange of GTP to GDP). Eventually,&#x000a0;this activity increases intracellular calcium concentration and promotes heart cell contraction.<xref ref-type="bibr" rid="article-657.r12">[12]</xref><xref ref-type="bibr" rid="article-657.r13">[13]</xref><xref ref-type="bibr" rid="article-657.r14">[14]</xref></p>
        <p>Activation of B1 receptors on juxtaglomerular cells leads to activating the renin-angiotensin system. Releasing renin&#x000a0;increases the production of angiotensin I, which is eventually converted by an angiotensin-converting enzyme (ACE) to angiotensin II.</p>
        <p>B2 receptors&#x000a0;are present in multiple body organs and are activated by epinephrine, leading to different manifestations according to the location involved. In peripheral vessels, it causes vasodilation and decreases peripheral resistance, opposing the effect of alpha-1 receptors, which cause vasoconstriction in the peripheral vessels. On the bronchioles, it leads to extensive bronchodilation. In addition, B2 receptor activation&#x000a0;in the liver and the muscles activates glycogenolysis and glucagon release, increasing blood sugar levels.</p>
        <p>Non-selective beta-blocker drugs block both the B1 and B2 receptors, decreasing cardiac output and decreasing renin release from the kidney. And B2 receptor blockage leads to additional manifestations&#x02014;vasoconstriction&#x000a0;of the peripheral vessels.&#x000a0;Blocking B2 receptors causes bronchial muscle contraction in the lung, leading to bronchospasm in patients with COPD or asthma. It also leads to decrease glycogenolysis and glucagon release, which may lead to hypoglycemia.<xref ref-type="bibr" rid="article-657.r9">[9]</xref><xref ref-type="bibr" rid="article-657.r15">[15]</xref></p>
        <p><bold>Pharmacokinetics</bold>&#x000a0;</p>
        <p>Absorption: Bisporolol is well absorbed, and the bioavailability of bisoprolol is&#x000a0;approximately&#x000a0;80%. The time to peak plasma concentration is approximately 2&#x000a0;to 4 hours. Steady-state plasma concentration&#x000a0;is achieved in 5 days.<xref ref-type="bibr" rid="article-657.r16">[16]</xref></p>
        <p>Distribution: Bisoprolol has low lipophilicity; penetration the through the blood-brain barrier is minimal. The volume of distribution of about 3.5 L/kg.<xref ref-type="bibr" rid="article-657.r17">[17]</xref></p>
        <p>Metabolism:&#x000a0;Bisoprolol is primarily metabolized by the CYP3A4 and CYP2D6(minor). First-pass metabolism of bisoprolol is low.<xref ref-type="bibr" rid="article-657.r18">[18]</xref></p>
        <p>Excretion: Bisoprolol is eliminated by&#x000a0; 50% renal excretion (unchanged drug) and 50% by&#x000a0;hepatic metabolism to pharmacologically inactive metabolites excreted by the kidneys. Tubular&#x000a0;secretion&#x000a0;plays an important role in the renal elimination of bisoprolol. Excretion through feces is approximately 2%. Bisoprolol fumarate has a long half-life that extends from&#x000a0;9 to 12 hours.<xref ref-type="bibr" rid="article-657.r19">[19]</xref><xref ref-type="bibr" rid="article-657.r20">[20]</xref></p>
      </sec>
      <sec id="article-657.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Cardioselective agents are either administered orally or intravenously.&#x000a0;Bisoprolol fumarate is administered orally as 5 or 10 mg tablets once daily.</p>
        <p>Hypertension: The dose of bisoprolol fumarate should be tailored to the patient's individualized needs. The usual starting dose is 5 mg once daily.&#x000a0;If the 5 mg dose does not produce the desired antihypertensive effect,&#x000a0; the dose should be gradually increased to 10 mg and then, if needed, to 20 mg once daily.<xref ref-type="bibr" rid="article-657.r21">[21]</xref></p>
        <p>Heart Failure With Reduced Ejection Fraction: The initial dose is 1.25 mg once daily, while the target dose is 10 mg once daily. To optimize GDMT, the dose should be titrated every 1 to 2 weeks based on&#x000a0;symptoms, vital signs, and volume status. Bisoprolol should be started once acute decompensated heart failure is stabilized, and the patient does not require vasopressors or inotropes.<xref ref-type="bibr" rid="article-657.r3">[3]</xref></p>
        <p>Atrial Fibrillation: According to AHA/ACC/HRS guidelines, the dose of bisoprolol for rate control is 2.5 mg to 10 mg PO once daily.<xref ref-type="bibr" rid="article-657.r22">[22]</xref><xref ref-type="bibr" rid="article-657.r23">[23]</xref></p>
        <p>Coronary Artery Disease: According to AHA/ACC/ASH guidelines, beta-blockers without intrinsic sympathomimetic activity, such as bisoprolol, should be used for CAD. The dose of bisoprolol is 5 to 10 mg once daily.&#x000a0;The drug should not be used for&#x000a0;variant angina (Prinzmetal angina).<xref ref-type="bibr" rid="article-657.r24">[24]</xref></p>
        <p>
<bold>Specific Populations</bold>
</p>
        <p>Hepatic Impairment:&#x000a0;According to the manufacturer's prescribing information in patients with hepatitis or cirrhosis, the initial daily dose should be 2.5 mg and, if needed, titrated upward slowly.</p>
        <p>Renal Impairment:&#x000a0;According to the manufacturer's prescribing information, in patients with&#x000a0;creatinine clearance less than 40 ml/min starting dose should be 2.5 mg per day, and titrate upwards slowly. Since limited data suggest that bisoprolol&#x000a0;fumarate is not dialyzable, dose adjustment is unnecessary for dialysis patients.</p>
        <p>Older&#x000a0;Patients:&#x000a0;The dose needs to be adjusted in&#x000a0;older patients only if there is significant hepatic or renal dysfunction.</p>
        <p>Pediatric Patients:&#x000a0;Product labeling has no information on pediatric experience with bisoprolol fumarate; there are no approved indications for pediatric patients.</p>
        <p>Pregnancy Considerations:&#x000a0;Bisoprolol is a former FDA category C medicine and should be used only if there are no other alternatives to its therapy. According to the ACOG (American College of Obstetricians and Gynecologists), labetalol might be preferred over bisoprolol to treat gestational hypertension.<xref ref-type="bibr" rid="article-657.r25">[25]</xref><xref ref-type="bibr" rid="article-657.r26">[26]</xref></p>
        <p>Breastfeeding Considerations:&#x000a0;The excretion of beta blockers in breast milk is primarily&#x000a0;determined by plasma protein binding (PPB). Low&#x000a0;plasma protein binding&#x000a0;is associated with&#x000a0;increased&#x000a0;excretion in breast milk. Bisoprolol&#x000a0;has low PPB&#x000a0;(30%), a long half-life, and a potential risk&#x000a0;of accumulation in infants.&#x000a0;In addition, there is minimal clinical&#x000a0;experience&#x000a0;in using bisoprolol during breastfeeding; consequently, other drugs are preferred, particularly if nursing a newborn or preterm infant.<xref ref-type="bibr" rid="article-657.r27">[27]</xref></p>
      </sec>
      <sec id="article-657.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>A common&#x000a0;adverse effect of cardiovascular blockers is bradycardia, decreasing heart rate and strength of contraction due to its negative chronotropic and inotropic effects. Bisoprolol also decreases cardiac output; therefore, it decreases exercise capacity. Blocking beta receptors on the SA and AV node always carries a risk of heart block. It correlates less frequently with exacerbating peripheral diseases such as the Raynaud phenomenon, bronchoconstriction, and hypoglycemia&#x000a0;than non-selective beta-blockers.<xref ref-type="bibr" rid="article-657.r28">[28]</xref></p>
        <p>Other commonly encountered&#x000a0;adverse effects include nausea, vomiting, and constipation. Hypoglycemia is a dangerous&#x000a0;adverse effect in people with diabetes using beta-blockers. The drug blocks the typical signs of hypoglycemia, such as tachycardia, delaying the body's normal response to hypoglycemia, possibly leading to fear of complications.<xref ref-type="bibr" rid="article-657.r29">[29]</xref>&#x000a0;</p>
        <p>Bradycardia, fatigue, asthenia, diarrhea, and sinusitis are dose-related among all adverse events. Beta-blockers, including bisoprolol,&#x000a0;are implicated in drug-induced psoriasis and the worsening of pre-existing psoriasis.<xref ref-type="bibr" rid="article-657.r30">[30]</xref><xref ref-type="bibr" rid="article-657.r31">[31]</xref><xref ref-type="bibr" rid="article-657.r32">[32]</xref>&#x000a0;</p>
        <p>Neuropsychiatric adverse events such as&#x000a0;insomnia may be caused by bisoprolol, but a recent study by AHA&#x000a0;found no association between bisoprolol use and depression.<xref ref-type="bibr" rid="article-657.r33">[33]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Abrupt discontinuation of clonidine while taking bisoprolol results&#x000a0;in a&#x000a0;catecholamine surge and can lead to rebound hypertension.&#x000a0;Bisoprolol should be stopped several days before the discontinuation of clonidine.<xref ref-type="bibr" rid="article-657.r34">[34]</xref></p>
          </list-item>
          <list-item>
            <p>Concomitant use of bisoprolol with calcium channel blockers such as verapamil and diltiazem may&#x000a0;worsen the myocardial function and&#x000a0;result in&#x000a0;hypotension, bradycardia, and AV block.<xref ref-type="bibr" rid="article-657.r35">[35]</xref></p>
          </list-item>
          <list-item>
            <p>Strong CYP3A4 induces, like rifampin, increases the clearance of bisoprolol, resulting in a short elimination half-life of bisoprolol.<xref ref-type="bibr" rid="article-657.r36">[36]</xref></p>
          </list-item>
          <list-item>
            <p>Concomitant administration of cholinesterase inhibitors like donepezil with bisoprolol can increase the risk for bradycardia, falls, and syncope.<xref ref-type="bibr" rid="article-657.r37">[37]</xref></p>
          </list-item>
          <list-item>
            <p>Concomitant use of&#x000a0;bisoprolol with digoxin&#x000a0;delays&#x000a0;AV conduction and can increase the risk of bradycardia.<xref ref-type="bibr" rid="article-657.r38">[38]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-657.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Cardioselective beta-blockers are contraindicated in patients with marked sinus bradycardia, cardiogenic shock, and complete heart block (third-degree AV block).<xref ref-type="bibr" rid="article-657.r39">[39]</xref>&#x000a0;Patients with second-degree&#x000a0;AV block&#x000a0;should be monitored carefully. In addition, patients&#x000a0;with a history of recent fluid retention should not use beta-blockers without the concomitant use of diuretics.<xref ref-type="bibr" rid="article-657.r40">[40]</xref>&#x000a0;</p>
        <p>New studies suggest that cardioselective beta-blockers are contraindicated in patients with severe asthma or COPD, while it is entirely safe in patients with mild to moderate diseases.<xref ref-type="bibr" rid="article-657.r41">[41]</xref>&#x000a0;</p>
        <p>In patients with diabetes,&#x000a0;beta blockers may mask hypoglycemia, so careful monitoring is necessary.<xref ref-type="bibr" rid="article-657.r42">[42]</xref>&#x000a0;Bisoprolol should not be abruptly withdrawn as&#x000a0;doing so can cause rebound hypertension and tachycardia. In addition, some patients have developed or exacerbated existing angina pectoris, myocardial infarction, or ventricular arrhythmia when cessed therapy abruptly. Gradual reduction of the dose is recommended.<xref ref-type="bibr" rid="article-657.r43">[43]</xref></p>
      </sec>
      <sec id="article-657.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>The essential components to monitor at every visit in patients on the cardioselective beta-blocker are blood pressure and heart rate to detect and prevent bradycardia and hypotension. The cardiac electricity level should be monitored to avoid any degree of heart block. Renal function tests and complete blood counts are not indicated for regular monitoring but are necessary when there is a suspicion of toxicity or if the physician is concerned about the therapeutic level of the medicine.<xref ref-type="bibr" rid="article-657.r28">[28]</xref>&#x000a0;</p>
        <p>The blood sugar level is regularly monitored in diabetic patients to prevent beta blocker-masked hypoglycemic episodes. Monitoring of lactate level is mandatory in a patient suspected of ingesting a high dose of beta-blockers due to the chance of having mesenteric ischemia.<xref ref-type="bibr" rid="article-657.r44">[44]</xref>&#x000a0;</p>
        <p>In case of maternal exposure to bisoprolol, monitor the newborn baby's HR, blood glucose, and respiratory rate for 48 hours after birth.<xref ref-type="bibr" rid="article-657.r25">[25]</xref>&#x000a0;Beta-blockers can worsen myasthenia gravis. Monitor for worsening of ptosis, diplopia, and muscle weakness.<xref ref-type="bibr" rid="article-657.r45">[45]</xref></p>
      </sec>
      <sec id="article-657.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>The toxicity of cardio-selective beta-blockers occurs after ingesting a high dose of the drug, either intentionally or unintentionally.&#x000a0;Toxicity can be asymptomatic in some patients, but treatment is always required. Patients in such cases usually present with bradycardia and hypotension. In addition, selective beta-blockers in high doses lose their selectivity, causing patients&#x000a0;to demonstrate signs of respiratory distress, congestive heart failure, and neurological manifestations, such as confusion and mental retardation, hypoglycemia, and hyperkalemia.</p>
        <p>The beta-blocker overdose treatment protocol includes several medicines based on the signs and symptoms of clinical toxicity.<xref ref-type="bibr" rid="article-657.r46">[46]</xref><xref ref-type="bibr" rid="article-657.r47">[47]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Sympathomimetic agents (IV atropine or&#x000a0;isoproterenol) are used in patients who experience bradycardia.</p>
          </list-item>
          <list-item>
            <p>To antagonize beta-blocker-induced hypotension, the clinician should administer intravenous glucagon and fluid. Epinephrine may be ineffective in anaphylaxis induced by beta blockers. Glucagon stimulates heart contraction by glucagon receptors, which are not blocked by beta-blockers.<xref ref-type="bibr" rid="article-657.r48">[48]</xref></p>
          </list-item>
          <list-item>
            <p>To reverse the bronchospasm induced by beta-blockers,&#x000a0;isoproterenol, and&#x000a0;aminophylline can be used.</p>
          </list-item>
          <list-item>
            <p>Depending on the patient's hemodynamic stability, hypoglycemia can be addressed by administering glucose orally or IV.</p>
          </list-item>
          <list-item>
            <p>The patient needs to be monitored carefully in case of a heart block and should be treated with isoproterenol infusion or&#x000a0;transvenous cardiac pacemaker insertion.<xref ref-type="bibr" rid="article-657.r49">[49]</xref></p>
          </list-item>
          <list-item>
            <p>Congestion and impaired perfusion status should be accurately determined in acute decompensated heart failure due to severe overdose. Digitalis,&#x000a0;diuretics, inotropic agents, and vasopressors&#x000a0;should be used according to hemodynamic status.<xref ref-type="bibr" rid="article-657.r50">[50]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-657.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Clinicians prescribe bisoprolol for hypertension, Heart failure with reduced ejection fraction, and coronary artery disease. Bisoprolol can mask the symptoms of hypoglycemia&#x000a0;in diabetes; drug interactions can lead to bradycardia and AV block. In addition, abrupt withdrawal of bisoprolol can be life-threatening as it can cause life-threatening tachycardia, rebound hypertension, and in some cases, angina.</p>
        <p>With careful monitoring of the patient's heart rate, blood pressure, temperature, and renal function, the clinician must know the possible&#x000a0;adverse drug reactions and their appropriate management. The cardiologist's&#x000a0;role is crucial in managing coronary artery disease. Arrhythmias refractory to bisoprolol therapy may require EP consultation.&#x000a0;Patient care delivered by heart failure specialists&#x000a0;is associated with lower&#x000a0;mortality rates.<xref ref-type="bibr" rid="article-657.r51">[51]</xref></p>
        <p>Pharmacists must be aware of the required doses of the drug for each patient and perform medication reconciliation. Nurses can counsel the patients regarding administration and, along with the pharmacist, counsel the patient on potential adverse effects. Pharmacists and nurses must report any issues with the therapy regimen to the prescribing clinician for corrective action. Bisoprolol toxicity from accidental overdose is also possible in a patient with hypertension, so it is essential to know how to antagonize the drug's effect using high-dose glucagon.&#x000a0;A study demonstrated that inpatient services delivered by&#x000a0;medical toxicologists&#x000a0;are&#x000a0;associated with&#x000a0;reduced length of stay&#x000a0;and mortality in poisoning and overdose.<xref ref-type="bibr" rid="article-657.r52">[52]</xref>&#x000a0;</p>
        <p>A psychiatrist consultation is required if the overdose of bisoprolol is intentional. An interprofessional team approach delivered by physicians, advanced practice practitioners, cardiologists, pulmonologists (for patients with asthma), pharmacists, specialty-trained nursing staff, and toxicologists can achieve optimal patient&#x000a0;outcomes related to bisoprolol therapy.</p>
      </sec>
      <sec id="article-657.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=657&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=657">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/657/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=657">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-657.s11">
        <title>References</title>
        <ref id="article-657.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Minushkina</surname>
                <given-names>LO</given-names>
              </name>
            </person-group>
            <article-title>[Bisoprolol: opportunities in the treatment of hypertension].</article-title>
            <source>Kardiologiia</source>
            <year>2012</year>
            <volume>52</volume>
            <issue>6</issue>
            <fpage>80</fpage>
            <page-range>80-5</page-range>
            <pub-id pub-id-type="pmid">22839675</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Whelton</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Aronow</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Dennison Himmelfarb</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>DePalma</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Gidding</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jamerson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>MacLaughlin</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Muntner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ovbiagele</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Stafford</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Taler</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</article-title>
            <source>Hypertension</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>71</volume>
            <issue>6</issue>
            <fpage>e13</fpage>
            <page-range>e13-e115</page-range>
            <pub-id pub-id-type="pmid">29133356</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heidenreich</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Bozkurt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Aguilar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Byun</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Colvin</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Deswal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Drazner</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Dunlay</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Evers</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Fedson</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Fonarow</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Hayek</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Hernandez</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Khazanie</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kittleson</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Milano</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Nnacheta</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Sandhu</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Vardeny</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Vest</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2022</year>
            <month>May</month>
            <day>03</day>
            <volume>79</volume>
            <issue>17</issue>
            <fpage>e263</fpage>
            <page-range>e263-e421</page-range>
            <pub-id pub-id-type="pmid">35379503</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wee</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Burns</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bett</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Medical management of chronic stable angina.</article-title>
            <source>Aust Prescr</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>38</volume>
            <issue>4</issue>
            <fpage>131</fpage>
            <page-range>131-6</page-range>
            <pub-id pub-id-type="pmid">26648642</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Unger</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Borghi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Charchar</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Poulter</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Prabhakaran</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ramirez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schlaich</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stergiou</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Tomaszewski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wainford</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schutte</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>2020 International Society of Hypertension Global Hypertension Practice Guidelines.</article-title>
            <source>Hypertension</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>75</volume>
            <issue>6</issue>
            <fpage>1334</fpage>
            <page-range>1334-1357</page-range>
            <pub-id pub-id-type="pmid">32370572</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Poldermans</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Boersma</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bax</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Thomson</surname>
                <given-names>IR</given-names>
              </name>
              <name>
                <surname>Paelinck</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>van de Ven</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Scheffer</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Trocino</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vigna</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Baars</surname>
                <given-names>HF</given-names>
              </name>
              <name>
                <surname>van Urk</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Roelandt</surname>
                <given-names>JR</given-names>
              </name>
              <collab>Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group</collab>
            </person-group>
            <article-title>Bisoprolol reduces cardiac death and myocardial infarction in high-risk patients as long as 2 years after successful major vascular surgery.</article-title>
            <source>Eur Heart J</source>
            <year>2001</year>
            <month>Aug</month>
            <volume>22</volume>
            <issue>15</issue>
            <fpage>1353</fpage>
            <page-range>1353-8</page-range>
            <pub-id pub-id-type="pmid">11465968</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cruickshank</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Beta-blockers and heart failure.</article-title>
            <source>Indian Heart J</source>
            <year>2010</year>
            <season>Mar-Apr</season>
            <volume>62</volume>
            <issue>2</issue>
            <fpage>101</fpage>
            <page-range>101-10</page-range>
            <pub-id pub-id-type="pmid">21180298</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ladage</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Schwinger</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Brixius</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Cardio-selective beta-blocker: pharmacological evidence and their influence on exercise capacity.</article-title>
            <source>Cardiovasc Ther</source>
            <year>2013</year>
            <month>Apr</month>
            <volume>31</volume>
            <issue>2</issue>
            <fpage>76</fpage>
            <page-range>76-83</page-range>
            <pub-id pub-id-type="pmid">22279967</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>do Vale</surname>
                <given-names>GT</given-names>
              </name>
              <name>
                <surname>Ceron</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Gonzaga</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Simplicio</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Padovan</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Three Generations of &#x003b2;-blockers: History, Class Differences and Clinical Applicability.</article-title>
            <source>Curr Hypertens Rev</source>
            <year>2019</year>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>22</fpage>
            <page-range>22-31</page-range>
            <pub-id pub-id-type="pmid">30227820</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Papadopoulos</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Papademetriou</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Low-dose fixed combination of bisoprolol/hydrochlorothiazide as first line for hypertension: a review of the rationale and clinical evidence.</article-title>
            <source>Angiology</source>
            <year>2009</year>
            <season>Oct-Nov</season>
            <volume>60</volume>
            <issue>5</issue>
            <fpage>601</fpage>
            <page-range>601-7</page-range>
            <pub-id pub-id-type="pmid">19028769</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johns</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Lopez</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Bisoprolol: is this just another beta-blocker for hypertension or angina?</article-title>
            <source>Ann Pharmacother</source>
            <year>1995</year>
            <month>Apr</month>
            <volume>29</volume>
            <issue>4</issue>
            <fpage>403</fpage>
            <page-range>403-14</page-range>
            <pub-id pub-id-type="pmid">7633020</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Galougahi</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Bundgaard</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rasmussen</surname>
                <given-names>HH</given-names>
              </name>
            </person-group>
            <article-title>&#x003b2;-Adrenergic regulation of the cardiac Na+-K+ ATPase mediated by oxidative signaling.</article-title>
            <source>Trends Cardiovasc Med</source>
            <year>2012</year>
            <month>May</month>
            <volume>22</volume>
            <issue>4</issue>
            <fpage>83</fpage>
            <page-range>83-7</page-range>
            <pub-id pub-id-type="pmid">23040838</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kamp</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Hell</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Regulation of cardiac L-type calcium channels by protein kinase A and protein kinase C.</article-title>
            <source>Circ Res</source>
            <year>2000</year>
            <month>Dec</month>
            <day>08</day>
            <volume>87</volume>
            <issue>12</issue>
            <fpage>1095</fpage>
            <page-range>1095-102</page-range>
            <pub-id pub-id-type="pmid">11110765</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kushnir</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marks</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>The ryanodine receptor in cardiac physiology and disease.</article-title>
            <source>Adv Pharmacol</source>
            <year>2010</year>
            <volume>59</volume>
            <fpage>1</fpage>
            <page-range>1-30</page-range>
            <pub-id pub-id-type="pmid">20933197</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ram</surname>
                <given-names>CV</given-names>
              </name>
            </person-group>
            <article-title>Beta-blockers in hypertension.</article-title>
            <source>Am J Cardiol</source>
            <year>2010</year>
            <month>Dec</month>
            <day>15</day>
            <volume>106</volume>
            <issue>12</issue>
            <fpage>1819</fpage>
            <page-range>1819-25</page-range>
            <pub-id pub-id-type="pmid">21126627</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ishida</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Horie</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nishimura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Taguchi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fujii</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nozawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hashimoto</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Variability of bioavailability and intestinal absorption characteristics of bisoprolol.</article-title>
            <source>Drug Metab Pharmacokinet</source>
            <year>2013</year>
            <volume>28</volume>
            <issue>6</issue>
            <fpage>491</fpage>
            <page-range>491-6</page-range>
            <pub-id pub-id-type="pmid">23719964</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chan</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>TTW</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Kong</surname>
                <given-names>APS</given-names>
              </name>
              <name>
                <surname>Tomlinson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Influence of <italic>CYP2D6</italic> and <italic>CYP3A5</italic> Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Bisoprolol in Hypertensive Chinese Patients.</article-title>
            <source>Front Med (Lausanne)</source>
            <year>2021</year>
            <volume>8</volume>
            <fpage>683498</fpage>
            <pub-id pub-id-type="pmid">34568359</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>&#x000c5;gesen</surname>
                <given-names>FN</given-names>
              </name>
              <name>
                <surname>Weeke</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Tfelt-Hansen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tfelt-Hansen</surname>
                <given-names>J</given-names>
              </name>
              <collab>for ESCAPE&#x02010;NET</collab>
            </person-group>
            <article-title>Pharmacokinetic variability of beta-adrenergic blocking agents used in cardiology.</article-title>
            <source>Pharmacol Res Perspect</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>7</volume>
            <issue>4</issue>
            <fpage>e00496</fpage>
            <pub-id pub-id-type="pmid">31338197</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>QS</given-names>
              </name>
            </person-group>
            <article-title>Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling.</article-title>
            <source>Acta Pharmacol Sin</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>33</volume>
            <issue>11</issue>
            <fpage>1359</fpage>
            <page-range>1359-71</page-range>
            <pub-id pub-id-type="pmid">23085739</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abeel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Constance</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Concomitant Treatment of Hypertensive Patients with Bisoprolol and Perindopril in Routine Clinical Practice: A Post Hoc Analysis of the CONFIDENCE&#x000a0;II, PROTECT&#x000a0;I, and PROTECT&#x000a0;III Observational Studies.</article-title>
            <source>Adv Ther</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>39</volume>
            <issue>1</issue>
            <fpage>391</fpage>
            <page-range>391-404</page-range>
            <pub-id pub-id-type="pmid">34755324</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bonelli</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Staribacher</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Haemodynamic effects of bisoprolol in patients with coronary heart disease: influence of various bisoprolol plasma concentrations.</article-title>
            <source>J Cardiovasc Pharmacol</source>
            <year>1986</year>
            <volume>8 Suppl 11</volume>
            <fpage>S83</fpage>
            <page-range>S83-6</page-range>
            <pub-id pub-id-type="pmid">2439805</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>January</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Wann</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Alpert</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Calkins</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cigarroa</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Cleveland</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Conti</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Ellinor</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Ezekowitz</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Field</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Sacco</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Tchou</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Tracy</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
              <collab>ACC/AHA Task Force Members</collab>
            </person-group>
            <article-title>2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.</article-title>
            <source>Circulation</source>
            <year>2014</year>
            <month>Dec</month>
            <day>02</day>
            <volume>130</volume>
            <issue>23</issue>
            <fpage>e199</fpage>
            <page-range>e199-267</page-range>
            <pub-id pub-id-type="pmid">24682347</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Muresan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cismaru</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Muresan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rosu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gusetu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Puiu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mada</surname>
                <given-names>RO</given-names>
              </name>
              <name>
                <surname>Martins</surname>
                <given-names>RP</given-names>
              </name>
            </person-group>
            <article-title>Beta-blockers for the treatment of arrhythmias: Bisoprolol&#x000a0;-&#x000a0;a systematic review.</article-title>
            <source>Ann Pharm Fr</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>80</volume>
            <issue>5</issue>
            <fpage>617</fpage>
            <page-range>617-634</page-range>
            <pub-id pub-id-type="pmid">35093388</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosendorff</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lackland</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Allison</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aronow</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Blumenthal</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Cannon</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>de Lemos</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Findeiss</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gersh</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Gore</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>O'Connor</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>O'Gara</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Ogedegbe</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Oparil</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>WB</given-names>
              </name>
              <collab>American Heart Association, American College of Cardiology, and American Society of Hypertension</collab>
            </person-group>
            <article-title>Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension.</article-title>
            <source>Circulation</source>
            <year>2015</year>
            <month>May</month>
            <day>12</day>
            <volume>131</volume>
            <issue>19</issue>
            <fpage>e435</fpage>
            <page-range>e435-70</page-range>
            <pub-id pub-id-type="pmid">25829340</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Regitz-Zagrosek</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Roos-Hesselink</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Bauersachs</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Blomstr&#x000f6;m-Lundqvist</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>C&#x000ed;fkov&#x000e1;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>De Bonis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Iung</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Kintscher</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Kranke</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Morais</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pieper</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Presbitero</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rosano</surname>
                <given-names>GMC</given-names>
              </name>
              <name>
                <surname>Seeland</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Simoncini</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Swan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Warnes</surname>
                <given-names>CA</given-names>
              </name>
              <collab>ESC Scientific Document Group</collab>
            </person-group>
            <article-title>2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy.</article-title>
            <source>Eur Heart J</source>
            <year>2018</year>
            <month>Sep</month>
            <day>07</day>
            <volume>39</volume>
            <issue>34</issue>
            <fpage>3165</fpage>
            <page-range>3165-3241</page-range>
            <pub-id pub-id-type="pmid">30165544</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <article-title>ACOG Practice Bulletin No. 202: Gestational Hypertension and Preeclampsia.</article-title>
            <source>Obstet Gynecol</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>133</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <pub-id pub-id-type="pmid">30575675</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r27">
          <label>27</label>
          <element-citation publication-type="book">
            <chapter-title>Bisoprolol</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000203</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r28">
          <label>28</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Tucker</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Sankar</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Theetha Kariyanna</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <chapter-title>Selective Beta-1 Blockers</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>1</month>
            <day>30</day>
            <pub-id pub-id-type="pmid">29763157</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fonseca</surname>
                <given-names>VA</given-names>
              </name>
            </person-group>
            <article-title>Effects of beta-blockers on glucose and lipid metabolism.</article-title>
            <source>Curr Med Res Opin</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>615</fpage>
            <page-range>615-29</page-range>
            <pub-id pub-id-type="pmid">20067434</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Milavec-Pureti&#x00107;</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mance</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ceovi&#x00107;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lipozen&#x0010d;i&#x00107;</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Drug induced psoriasis.</article-title>
            <source>Acta Dermatovenerol Croat</source>
            <year>2011</year>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>39</fpage>
            <page-range>39-42</page-range>
            <pub-id pub-id-type="pmid">21489366</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Awad</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Sakhamuru</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kambampati</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wasim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Malik</surname>
                <given-names>BH</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of Beta-Blocker Induced Psoriasis, and Psoriasis De Novo at the Cellular Level.</article-title>
            <source>Cureus</source>
            <year>2020</year>
            <month>Jul</month>
            <day>02</day>
            <volume>12</volume>
            <issue>7</issue>
            <fpage>e8964</fpage>
            <pub-id pub-id-type="pmid">32766006</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Waqar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sarkar</surname>
                <given-names>PK</given-names>
              </name>
            </person-group>
            <article-title>Exacerbation of psoriasis with beta-blocker therapy.</article-title>
            <source>CMAJ</source>
            <year>2009</year>
            <month>Jul</month>
            <day>07</day>
            <volume>181</volume>
            <issue>1-2</issue>
            <fpage>60</fpage>
            <pub-id pub-id-type="pmid">19581619</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scheer</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Smales</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Marks</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Malhotra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shea</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Repeated melatonin supplementation improves sleep in hypertensive patients treated with beta-blockers: a randomized controlled trial.</article-title>
            <source>Sleep</source>
            <year>2012</year>
            <month>Oct</month>
            <day>01</day>
            <volume>35</volume>
            <issue>10</issue>
            <fpage>1395</fpage>
            <page-range>1395-402</page-range>
            <pub-id pub-id-type="pmid">23024438</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Handler</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Adverse effects using combined rate-slowing antihypertensive agents.</article-title>
            <source>J Clin Hypertens (Greenwich)</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>13</volume>
            <issue>7</issue>
            <fpage>529</fpage>
            <page-range>529-32</page-range>
            <pub-id pub-id-type="pmid">21762367</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saedder</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Thomsen</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Hasselstr&#x000f8;m</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Jornil</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Heart insufficiency after combination of verapamil and metoprolol: A fatal case report and literature review.</article-title>
            <source>Clin Case Rep</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>7</volume>
            <issue>11</issue>
            <fpage>2042</fpage>
            <page-range>2042-2048</page-range>
            <pub-id pub-id-type="pmid">31788248</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Benet</surname>
                <given-names>LZ</given-names>
              </name>
              <name>
                <surname>Zhai</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Predicting Interactions between Rifampin and Antihypertensive Drugs Using the Biopharmaceutics Drug Disposition Classification System.</article-title>
            <source>Pharmacotherapy</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>40</volume>
            <issue>4</issue>
            <fpage>274</fpage>
            <page-range>274-290</page-range>
            <pub-id pub-id-type="pmid">32100890</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hernandez</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Farwell</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Cantor</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Lawler</surname>
                <given-names>EV</given-names>
              </name>
            </person-group>
            <article-title>Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs new England healthcare system.</article-title>
            <source>J Am Geriatr Soc</source>
            <year>2009</year>
            <month>Nov</month>
            <volume>57</volume>
            <issue>11</issue>
            <fpage>1997</fpage>
            <page-range>1997-2003</page-range>
            <pub-id pub-id-type="pmid">19793162</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>MacLeod-Glover</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mink</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yarema</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chuang</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Digoxin toxicity: Case for retiring its use in elderly patients?</article-title>
            <source>Can Fam Physician</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>62</volume>
            <issue>3</issue>
            <fpage>223</fpage>
            <page-range>223-8</page-range>
            <pub-id pub-id-type="pmid">26975913</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Osmonov</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Erdinler</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ozcan</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Altay</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Turkkan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yildirim</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hasdemir</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Alper</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Cakmak</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Satilmis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gurkan</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Management of patients with drug-induced atrioventricular block.</article-title>
            <source>Pacing Clin Electrophysiol</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>35</volume>
            <issue>7</issue>
            <fpage>804</fpage>
            <page-range>804-10</page-range>
            <pub-id pub-id-type="pmid">22530749</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cowie</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Recent developments in the management of heart failure.</article-title>
            <source>Practitioner</source>
            <year>2012</year>
            <month>Jun</month>
            <volume>256</volume>
            <issue>1752</issue>
            <fpage>25</fpage>
            <page-range>25-9, 3</page-range>
            <pub-id pub-id-type="pmid">22916582</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salpeter</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Ormiston</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Salpeter</surname>
                <given-names>EE</given-names>
              </name>
            </person-group>
            <article-title>Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis.</article-title>
            <source>Ann Intern Med</source>
            <year>2002</year>
            <month>Nov</month>
            <day>05</day>
            <volume>137</volume>
            <issue>9</issue>
            <fpage>715</fpage>
            <page-range>715-25</page-range>
            <pub-id pub-id-type="pmid">12416945</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mom&#x0010d;ilovi&#x00107;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jovanovi&#x00107;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Radojkovi&#x00107;</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nikoli&#x00107;</surname>
                <given-names>VN</given-names>
              </name>
              <name>
                <surname>Jankovi&#x00107;</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Pe&#x00161;i&#x00107;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Milovanovi&#x00107;</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Population pharmacokinetic analysis of bisoprolol in type 2 diabetic patients with hypertension.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>76</volume>
            <issue>11</issue>
            <fpage>1539</fpage>
            <page-range>1539-1546</page-range>
            <pub-id pub-id-type="pmid">32583355</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koracevic</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Micic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stojanovic</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>By Discontinuing Beta-Blockers Before an Exercise Test, We may Precipitate a Rebound Phenomenon.</article-title>
            <source>Curr Vasc Pharmacol</source>
            <year>2021</year>
            <volume>19</volume>
            <issue>6</issue>
            <fpage>624</fpage>
            <page-range>624-633</page-range>
            <pub-id pub-id-type="pmid">33653252</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bala</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Catena</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kashuk</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>De Simone</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gomes</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sartelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Coccolini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kluger</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Abu-Zidan</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Picetti</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ansaloni</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Augustin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Biffl</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Ceresoli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chiara</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Chiarugi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Coimbra</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cui</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Damaskos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Di Saverio</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Galante</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Khokha</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kirkpatrick</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Inaba</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lepp&#x000e4;niemi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Litvin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Peitzman</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Shelat</surname>
                <given-names>VG</given-names>
              </name>
              <name>
                <surname>Sugrue</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tolonen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rizoli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sall</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Beka</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Di Carlo</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ten Broek</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mircea</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tebala</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pisano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van Goor</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Maier</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>Jeekel</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Civil</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hecker</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Soreide</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Wani</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Bonavina</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Malangoni</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Koike</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Velmahos</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Fraga</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Fette</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>de'Angelis</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Balogh</surname>
                <given-names>ZJ</given-names>
              </name>
              <name>
                <surname>Scalea</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Sganga</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stahel</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>EE</given-names>
              </name>
            </person-group>
            <article-title>Acute mesenteric ischemia: updated guidelines of the World Society of Emergency Surgery.</article-title>
            <source>World J Emerg Surg</source>
            <year>2022</year>
            <month>Oct</month>
            <day>19</day>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>54</fpage>
            <pub-id pub-id-type="pmid">36261857</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trillenberg</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Katalinic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thern</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Graf</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>The risk of worsening of myasthenia by cardiovascular medication as reflected by reporting frequency.</article-title>
            <source>Eur J Neurol</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>28</volume>
            <issue>9</issue>
            <fpage>2965</fpage>
            <page-range>2965-2970</page-range>
            <pub-id pub-id-type="pmid">34184370</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shepherd</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Treatment of poisoning caused by beta-adrenergic and calcium-channel blockers.</article-title>
            <source>Am J Health Syst Pharm</source>
            <year>2006</year>
            <month>Oct</month>
            <day>01</day>
            <volume>63</volume>
            <issue>19</issue>
            <fpage>1828</fpage>
            <page-range>1828-35</page-range>
            <pub-id pub-id-type="pmid">16990629</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lauterbach</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Clinical toxicology of beta-blocker overdose in adults.</article-title>
            <source>Basic Clin Pharmacol Toxicol</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>125</volume>
            <issue>2</issue>
            <fpage>178</fpage>
            <page-range>178-186</page-range>
            <pub-id pub-id-type="pmid">30916882</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murakami</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kaneko</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yokoyama</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ishizaki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sekino</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Murata</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hara</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Successful treatment of severe adrenaline-resistant anaphylactic shock with glucagon in a patient taking a beta-blocker: a case report.</article-title>
            <source>JA Clin Rep</source>
            <year>2021</year>
            <month>Dec</month>
            <day>15</day>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>86</fpage>
            <pub-id pub-id-type="pmid">34907487</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tjong</surname>
                <given-names>FVY</given-names>
              </name>
              <name>
                <surname>de Ruijter</surname>
                <given-names>UW</given-names>
              </name>
              <name>
                <surname>Beurskens</surname>
                <given-names>NEG</given-names>
              </name>
              <name>
                <surname>Knops</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>A comprehensive scoping review on transvenous temporary pacing therapy.</article-title>
            <source>Neth Heart J</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>27</volume>
            <issue>10</issue>
            <fpage>462</fpage>
            <page-range>462-473</page-range>
            <pub-id pub-id-type="pmid">31392624</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raj</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Maidman</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Adhyaru</surname>
                <given-names>BB</given-names>
              </name>
            </person-group>
            <article-title>Inpatient management of acute decompensated heart failure.</article-title>
            <source>Postgrad Med J</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>96</volume>
            <issue>1131</issue>
            <fpage>33</fpage>
            <page-range>33-42</page-range>
            <pub-id pub-id-type="pmid">31515438</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sims</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kalininskiy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yanamandala</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Josephs</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rivas-Lasarte</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Assa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jahufar</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rahgozar</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>SZ</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Saeed</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Murthy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jorde</surname>
                <given-names>UP</given-names>
              </name>
            </person-group>
            <article-title>Full-Time Cardiac Intensive Care Unit Staffing by Heart Failure Specialists and its Association with Mortality Rates.</article-title>
            <source>J Card Fail</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>28</volume>
            <issue>3</issue>
            <fpage>394</fpage>
            <page-range>394-402</page-range>
            <pub-id pub-id-type="pmid">34634449</pub-id>
          </element-citation>
        </ref>
        <ref id="article-657.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Curry</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Brooks</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Skolnik</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Gerkin</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Glenn</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Effect of a medical toxicology admitting service on length of stay, cost, and mortality among inpatients discharged with poisoning-related diagnoses.</article-title>
            <source>J Med Toxicol</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>65</fpage>
            <page-range>65-72</page-range>
            <pub-id pub-id-type="pmid">25127915</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
